teaser
Shire plc, the global specialty biopharmaceutical company, will present scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments Vyvanse (lisdexamfetamine dimesylate) Capsules CII and INTUNIV (guanfacine) Extended Release Tablets at two national scientific meetings for psychiatrists May 20-26, 2010 in New Orleans, LA.
“We believe that the Vyvanse and INTUNIV study findings will be an important contribution to the current collection of ADHD research. These studies reflect Shire’s commitment to advancing ADHD treatment research,” said Jeffrey Jonas, MD, Senior Vice President of Research & Development of Shire Pharmaceuticals Inc.
Key scientific presentations at these conferences are summarized below. Information about data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.
For more information, please click the link below:
Shire
